Japan’s aid policies to COVID-19
For Developing countries

Overview

Human Security is in crisis facing the spread of infectious diseases.

Providing medical and health assistance bilaterally, and
through international organizations.

Establishing the COVID-19 Crisis Response Emergency
Support Loan in order to help revitalize economic
activities.

Bilateral

Health care systems

Provision of medical equipment to more than 89 countries across
the globe ($436 million)
✓ X-ray equipment, thermographic cameras, ambulances, etc.

JICA’s technical cooperation
To 45 countries ($13 million)
✓ Japan has provided training for medical workers to prevent
infections and control outbreaks in health facilities, including through
providing testing equipment and protective gear.

Economic Recovery

COVID-19 Crisis Response Emergency Support Loan
(up to $4.5 billion over the next two years)
✓ As of December 2020, Japan has decided to extend Yen loans to
following countries;
  - the Philippines (approx. $450 million)
  - Indonesia (approx. $450 million)
  - India (approx. $450 million)
  - Bangladesh (approx. $320 million)
  - Maldives (approx. $45 million)
  - Mongolia (approx. $227 million)
  - Cambodia (approx. $227 million).

Multilateral

Health care systems

via UNICEF
To 66 countries of Asia-Oceania, the Middle East and Africa
✓ Provision of sanitary goods, training of health care workers on prevention
and raising awareness about the risk of infections

via UNDP
To 29 countries of Asia-Oceania, the Middle East and Africa
✓ Training the capacity of ministries related to health for the development
and implementation of health plans
✓ Provision of non-health equipment like electric generator and assistance
to health care waste management

via UNHCR
To refugees and other concerned persons in 17 countries of Asia and the Middle
East
✓ Provision of hygiene items, dissemination of COVID-19
information and training of health care workers on infectious diseases

Vaccine
via CEPI
✓ Funding pharmaceutical companies and labs to promote vaccine
development and clinical trials

via Gavi
✓ Support for vaccination infrastructure to popularize available vaccine